OBJECTIVE: Serum amyloid A (SAA) is an acute phase response protein and has apolipoprotein properties. Since type 2 diabetes is associated with chronic subclinical inflammation, the objective of this study is to investigate the changes in SAA level in type 2 diabetic patients and to evaluate the relationship between SAA and the capacity of serum to induce cellular cholesterol efflux via the two known cholesterol transporters, scavenger receptor class B type I (SR-BI) and ATP-binding cassette transporter G1 (ABCG1). METHODS: 264 patients with type 2 diabetes mellitus (42% with normoalbuminuria, 30% microalbuminuria, and 28% proteinuria) and 275 non-diabetic controls were recruited. SAA was measured by ELISA. SR-BI and ABCG1-mediated cholesterol efflux to serum were determined by measuring the transfer of [(3)H]cholesterol from Fu5AH rat hepatoma cells expressing SR-BI and from human ABCG1-transfected CHO-K1 cells to the medium containing the tested serum respectively. RESULTS: SAA was significantly increased in diabetic patients with incipient or overt nephropathy. Both SR-BI and ABCG1-mediated cholesterol efflux to serum were significantly impaired in all three groups of diabetic patients (p < 0.01). SAA inversely correlated with SR-BI-mediated cholesterol efflux (r = -0.36, p < 0.01) but did not correlate with ABCG1-mediated cholesterol efflux. Stepwise linear regression analysis showed that HDL, the presence or absence of diabetes, and log(SAA) were significant independent determinants of SR-BI-mediated cholesterol efflux to serum. CONCLUSION: SAA was increased in type 2 diabetic patients with incipient or overt nephropathy, and SAA was associated with impairment of SR-BI-mediated cholesterol efflux to serum.
OBJECTIVE:Serum amyloid A (SAA) is an acute phase response protein and has apolipoprotein properties. Since type 2 diabetes is associated with chronic subclinical inflammation, the objective of this study is to investigate the changes in SAA level in type 2 diabeticpatients and to evaluate the relationship between SAA and the capacity of serum to induce cellular cholesterol efflux via the two known cholesterol transporters, scavenger receptor class B type I (SR-BI) and ATP-binding cassette transporter G1 (ABCG1). METHODS: 264 patients with type 2 diabetes mellitus (42% with normoalbuminuria, 30% microalbuminuria, and 28% proteinuria) and 275 non-diabetic controls were recruited. SAA was measured by ELISA. SR-BI and ABCG1-mediated cholesterol efflux to serum were determined by measuring the transfer of [(3)H]cholesterol from Fu5AH rathepatoma cells expressing SR-BI and from humanABCG1-transfected CHO-K1 cells to the medium containing the tested serum respectively. RESULTS:SAA was significantly increased in diabeticpatients with incipient or overt nephropathy. Both SR-BI and ABCG1-mediated cholesterol efflux to serum were significantly impaired in all three groups of diabeticpatients (p < 0.01). SAA inversely correlated with SR-BI-mediated cholesterol efflux (r = -0.36, p < 0.01) but did not correlate with ABCG1-mediated cholesterol efflux. Stepwise linear regression analysis showed that HDL, the presence or absence of diabetes, and log(SAA) were significant independent determinants of SR-BI-mediated cholesterol efflux to serum. CONCLUSION:SAA was increased in type 2 diabeticpatients with incipient or overt nephropathy, and SAA was associated with impairment of SR-BI-mediated cholesterol efflux to serum.
Keywords:
ATP-binding cassette transporter G1; Cellular cholesterol efflux; High density lipoprotein; Reverse cholesterol transport; Scavenger receptor class B type I; Serum amyloid A
Authors: Tomáš Vaisar; Chongren Tang; Ilona Babenko; Patrick Hutchins; Jake Wimberger; Anthony F Suffredini; Jay W Heinecke Journal: J Lipid Res Date: 2015-05-20 Impact factor: 5.922
Authors: Edson M de Oliveira; Thais P Ascar; Jacqueline C Silva; Silvana Sandri; Silene Migliorini; Ricardo A Fock; Ana Campa Journal: Diabetologia Date: 2016-04-28 Impact factor: 10.122
Authors: Chang Yeop Han; Chongren Tang; Myriam E Guevara; Hao Wei; Tomasz Wietecha; Baohai Shao; Savitha Subramanian; Mohamed Omer; Shari Wang; Kevin D O'Brien; Santica M Marcovina; Thomas N Wight; Tomas Vaisar; Maria C de Beer; Frederick C de Beer; William R Osborne; Keith B Elkon; Alan Chait Journal: J Clin Invest Date: 2015-12-07 Impact factor: 14.808
Authors: Elena M Yubero-Serrano; Juan F Alcalá-Diaz; Diego Gómez-Coronado; Jose Lopez-Miranda; Francisco M Gutierrez-Mariscal; Antonio P Arenas-de Larriva; Patricia J Peña-Orihuela; Ruth Blanco-Rojo; Javier Martinez-Botas; Jose D Torres-Peña; Pablo Perez-Martinez; Jose M Ordovas; Javier Delgado-Lista Journal: Cardiovasc Diabetol Date: 2021-03-25 Impact factor: 9.951
Authors: Laura J den Hartigh; Shari Wang; Leela Goodspeed; Yilei Ding; Michelle Averill; Savitha Subramanian; Tomasz Wietecha; Kevin D O'Brien; Alan Chait Journal: PLoS One Date: 2014-09-24 Impact factor: 3.240
Authors: Hussein N Yassine; Olgica Trenchevska; Huijuan He; Chad R Borges; Dobrin Nedelkov; Wendy Mack; Naoko Kono; Juraj Koska; Peter D Reaven; Randall W Nelson Journal: PLoS One Date: 2015-01-21 Impact factor: 3.240
Authors: Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Marleen M J van Greevenbroek; Carla J H van der Kallen; Casper G Schalkwijk; Coen D A Stehouwer; Robin P F Dullaart; Uwe J F Tietge Journal: Sci Rep Date: 2016-06-08 Impact factor: 4.379